2014•Journal watchRequires access
An NRTI-Sparing Regimen for HIV-Infected, Treatment-Naive Patients?
Carlos del Rı́o
Open publisher page 0 citations
Abstract
For antiretroviral treatment–naive individuals, several regimens are recommended; all include two nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; either tenofovir/FTC or abacavir/lamivudine). Because of tolerability and toxicity issues with NRTIs, researchers have been investigating NRTI-free regimens for initial therapy.
In a randomized, open-label, noninferiority trial involving 805 treatment-naive HIV-infected individuals in 15 European countries (88% men, 82% white, 72% men who have sex with men, 4% with hepatitis C virus coinfection), researchers compared ritonavir-boosted darunavir (100/800 mg daily) plus raltegravir (400 mg twice daily) …